916257-05-1

Basic information

• Product Name: 1H-Pyrazole-4-carboxaldehyde, 1-[(4-methylphenyl)sulfonyl]-
• CAS NO: 916257-05-1
• Molecular Formula: C11H10N2O3S
• Molecular Weight: 250.278
• Mol File: 916257-05-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazole-4-carboxaldehyde, 1-[(4-methylphenyl)sulfonyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole-4-carboxaldehyde, 1-[(4-methylphenyl)sulfonyl]-(916257-05-1)
• EPA Substance Registry System: 1H-Pyrazole-4-carboxaldehyde, 1-[(4-methylphenyl)sulfonyl]-(916257-05-1)

Safety Data

• Hazardous Substances Data: 916257-05-1(Hazardous Substances Data)

Usage

Molecular Weight

267.32 g/mol

Structure

A pyrazole core with a carboxaldehyde group (-CHO) and a sulfonyl group (-SO2) attached to a 4-methylphenyl group.

Class

Pyrazole derivatives

Biological Activity

Potential applications in the development of new drugs and the study of molecular interactions and signaling pathways.

Use in Research

Commonly used in organic synthesis and pharmaceutical research.

Reactivity

Unique structure and reactivity make it a valuable building block for the synthesis of more complex organic molecules.

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 35344-95-7 1H-pyrazole-4-carbaldehyde 
• 930768-36-8 (1-tosyl-1H-pyrazol-4-yl)methanol 

Relevant articles and documents

An investigation into the role of 2,6-lutidine as an additive for the RuCl3-NaIO4 mediated oxidative cleavage of olefins to ketones

2,6-Lutidine has been identified as a beneficial additive for the oxidative cleavage of olefins to ketones by NaIO4 in the presence of catalytic RuCl3, improving the yield and shortening the reaction times. In the absence of 2,6-lutidine reactions stalled at the diol intermediate with incomplete conversion to the desired ketones. The reaction protocol described herein also avoids the use of harmful solvents such as CCl4 and DCE and is tolerant of a range of functional groups.

AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.